Vitamin C for Upper Respiratory Tract Infections
Given the consistent effect of vitamin C on reducing the duration and severity of URTIs, combined with its low cost and excellent safety profile, it is reasonable to recommend vitamin C supplementation for patients with common cold and upper respiratory infections, though it does not prevent infection occurrence.
Evidence Quality and Recommendation Basis
The 2020 European Position Paper on Rhinosinusitis (EPOS) provides Level Ia evidence supporting vitamin C use for URTIs 1. This represents the highest quality guideline evidence available, synthesizing multiple systematic reviews and meta-analyses.
Clinical Effects of Vitamin C
Duration of Illness
- Vitamin C supplementation significantly reduces the duration of URTI symptoms 1, 2
- Meta-analysis demonstrates a reduction of approximately 1.6 days in symptom duration in children 3
- The effect is consistent across multiple studies, showing shortened duration of fever, chest pain, chills, and bodily aches 4
Severity of Symptoms
- Vitamin C demonstrates consistent effects on reducing symptom severity, particularly for fever and chills 1, 4
- Evidence shows improvement in respiratory symptoms and reduced chest pain 4
- In children under 6 years, vitamin C combined with echinacea shows enhanced effectiveness 3
Prevention vs. Treatment
- Vitamin C does NOT significantly prevent URTI occurrence (RR 0.94,95% CI 0.87-1.01, P=0.09) 2
- The preventive effect is statistically insignificant, though there is a trend toward benefit 2, 3
- The primary benefit is therapeutic rather than prophylactic 1
Dosing Recommendations
Based on the guideline evidence:
- For treatment: Standard supplementation doses used in studies showing benefit 1
- Timing: Should be initiated at symptom onset for maximum benefit 4
- Duration: Continue throughout the illness course 1
The evidence does not specify exact therapeutic doses in the guidelines, though research studies used doses ranging from 125-2000 mg daily 5.
Safety Profile
- Vitamin C has an excellent safety profile with minimal adverse events 1
- No serious adverse events reported in systematic reviews 5, 3
- The low cost and safety make it a low-risk intervention worth trying 1
Clinical Algorithm for Use
- At symptom onset: Initiate vitamin C supplementation immediately 4
- Continue throughout illness: Maintain supplementation until symptoms resolve 1
- Combine with other symptomatic treatments: Use alongside antihistamine-analgesic-decongestant combinations, NSAIDs, or decongestants as needed 6
- Consider zinc supplementation: Add zinc lozenges (≥75 mg/day) within 24 hours of symptom onset for additional benefit 1, 6
Important Caveats and Pitfalls
What Vitamin C Does NOT Do
- Does not replace antibiotics when bacterial infection is present 1
- Does not prevent URTI occurrence in most populations 2, 3
- Should not delay appropriate medical evaluation for severe symptoms 7
Common Misconceptions
- Vitamin C is not a substitute for appropriate medical care in severe illness 7
- The benefit is modest but consistent, not dramatic 1, 2
- Individual response may vary, justifying a trial-and-error approach 1
Special Populations
- Children under 6 years: May benefit more, especially when combined with echinacea 3
- Athletes: Post-exercise URTI symptoms may be reduced with vitamin C supplementation 8
- Critically ill patients: IV vitamin C may have additional benefits in hospital settings, but this is beyond the scope of simple URTI management 4
Comparison with Other Treatments
Vitamin C shows comparable or superior benefit to several other commonly used interventions:
- More evidence than Echinacea, which has not been shown to provide significant benefits 1
- Similar rationale to zinc, which also reduces duration when started early 1
- Better safety profile than decongestants, which should only be used short-term 1, 6
- No antimicrobial resistance concerns unlike inappropriate antibiotic use 1, 6
Bottom Line for Clinical Practice
Recommend vitamin C supplementation to patients with URTI symptoms, emphasizing that it will likely shorten illness duration by 1-2 days and reduce symptom severity, but will not prevent infection or replace other appropriate treatments 1, 2, 3. The recommendation is strengthened by the intervention's safety, low cost, and consistent evidence base from high-quality guidelines 1.